No retraction, correction or concern found when last checked on Oct 23, 2026.

Cancer drug resistance: redox resetting renders a way

Yuan Liu, Qifu Li, Li Zhou and 5 more

Oncotarget · 2016 · Review

Abstract

// Yuan Liu 1,2,* , Qifu Li 2,* , Li Zhou 1,* , Na Xie 1 , Edouard C. Nice 3 , Haiyuan Zhang 2 , Canhua Huang 1 and Yunlong Lei 4 1 State Key Laboratory for Biotherapy and Cancer Center, West China Hospital, Sichuan University, and Collaborative Innovation Center of Biotherapy, Chengdu, P. R. China 2 Department of Neurology, The Affiliated Hospital of Hainan Medical College, Haikou, Hainan, P. R. China 3 Department of Biochemistry and Molecular Biology, Monash University, Clayton, Victoria, Australia 4 Department of Biochemistry and Molecular Biology, and Molecular Medicine and Cancer Research Center, Chongqing Medical University, Chongqing, P. R. China * These authors have contributed equally to this work Correspondence to: Yunlong Lei, email: // Canhua Huang, email: // Haiyuan Zhang, email: // Keywords : drug resistance, cancer therapy, oxidative stress, redox modifications, drug efflux Received : October 28, 2015 Accepted : March 28, 2016 Published : April 05, 2016 Abstract Disruption of redox homeostasis is a crucial factor in the development of drug resistance, which is a major problem facing current cancer treatment. Compared with normal cells, tumor cells generally exhibit higher levels of reactive oxygen species (ROS), which can promote tumor progression and development. Upon drug treatment, some tumor cells can undergo a process of ‘Redox Resetting’ to acquire a new redox balance with higher levels of ROS accumulation and stronger antioxidant systems. Evidence has accumulated showing that the ‘Redox Resetting’ enables cancer cells to become resistant to anticancer drugs by multiple mechanisms, including increased rates of drug efflux, altered drug metabolism and drug targets, activated prosurvival pathways and inefficient induction of cell death. In this article, we provide insight into the role of ‘ Redox Resetting ’ on the emergence of drug resistance that may contribute to pharmacological modulation of resistance.

Full text

From PubMed Central, U.S. National Library of Medicine, as current on Oct 23, 2026. Paragraph numbers are ours, so an answer can point at one.

INTRODUCTION

1Development of drug resistance is an important factor in the failure of anticancer therapeutic treatments. Such resistance results from a variety of factors including individual variations in patients and somatic cell genetic differences in tumors. The ability to evade medicinal drugs is intrinsic to cancer cells. Reasons for acquisition of anticancer drug resistance include enhanced expression of transporters that increases anticancer drugs efflux, alterations in drug metabolism, mutations of drug targets and the activation of survival or inactivation of downstream death signaling pathways (Figure 1). Studies on cancer drug resistance mechanisms have yielded valuable information on how to circumvent resistance to improve cancer chemotherapy.

2Reactive oxygen species (ROS) are chemical oxygen species with reactive properties, which comprise hydrogen peroxide (H2O2), the hydroxyl radical (•OH), superoxide(O2−) and singlet oxygen (1O2). Under physiological conditions, cells are capable of maintaining a balance between cellular oxidants and antioxidants, called redox homeostasis. Submicromolar levels of ROS act as second messengers to regulate cell proliferation, cell death, and other cellular processes. Excessive levels of ROS induce oxidative stress that leads to various pathological states, including aging, neurological disorders, and cancer. In general, most tumors exhibit higher levels of ROS than normal tissues, thus promoting tumor progression and development. Moreover, oxidative stress controls the efficacy of cancer treatments in multiple ways, including chemosensitivity, apoptosis, angiogenesis, metastasis and inflammatory responses. However, when ROS concentrations become extremely high, they lead to tumor cell death. Thus, a variety of drugs with direct or indirect effects on ROS induction have been used for effective cancer therapies (Table 1). Nonetheless, some tumor cells can overcome drug-induced oxidative stress by enhancing their antioxidant systems, with the outcome that a new redox balance with a more higher ROS level is established, the process of ‘Redox Resetting’ (Figure 2). Such drug-induced redox resetting has recently been shown to result in drug resistance. For example, increased levels of reduced glutathione lead to elevated chemotherapeutic drug resistance in numerous cancers.

3Redox resetting has been implicated in drug resistance at multiple levels, including elevated drug efflux, altered drug metabolism and mutated drug targets. In addition, ROS-induced activation of survival signaling pathways and inactivation of downstream death signaling pathways can lead to drug resistance (Figure 1). Here, we focus on the effects of redox resetting on drug resistance mechanisms and on current research efforts to reveal the detailed mechanisms of resistance to cancer therapies.

INCREASED RATES OF DRUG EFFLUX

4Drug export from cells is a primary cause of the cellular resistance to anticancer drugs and poses a significant threat to clinical tumor therapy. Several cell membrane transporter proteins have been implicated in drug resistance to commonly used chemotherapeutics by promoting drug efflux. Among them, the ATP-binding cassette (ABC) transporter family is the most notable. There are 49 members of the ABC transporter family, but only multi-drug resistance protein 1 (MDR1), MDR-associated protein 1 (MRP1) and breast cancer resistance protein (BCRP) have been studied extensively in relation to multidrug resistance (MDR). All three transporters have broad substrate specificity and promote the efflux of various hydrophobic cancer chemotherapeutics such as topoisomerase inhibitors, taxanes, and antimetabolites. Here, we summarize the effects of redox reactions and redox signals on these three drug efflux transporters.

Redox reactions promote conformational changes of the transporters

5All ABC transporters contain four domains - two nucleotide-binding domains (NBDs) and two transmembrane domains (TMDs) (Figure 3). These four domains can be fused into multi-domain polypeptides in a variety of ways. The driving force for drug transport is achieved by a switch between two principal conformations of the NBD dimer. The conformations of ABC transporters are maintained by multiple chemical interactions, including covalent bonds—the intra- and inter-molecular disulfide bond formed between reactive cysteine residues. The cellular redox status has a great impact on reversible disulfide bond formation and is essential for proper protein folding as well as transporter functions.

6The drug transport activity of human MDR1 is correlated with the redox states of its two cysteine residues (Cys431 and Cys1074). The ATP hydrolysis activity is strongly inhibited by the covalent reaction of either of these two cysteine residues with N-ethylmaleimide (NEM), a sulfhydryl blocker. These two cysteine residues are present in NBD1 and NBD2 (Figure 3A), and are located very close to the bound nucleotide. The ready formation of the intramolecular disulfide between Cys431 and Cys1074 shows that the two nucleotide-binding sites of MDR1 are structurally very close and capable of intimate functional interactions, consistent with our current understanding of the catalytic mechanism.

7MRP1 has a topological configuration similar to MDR1, whereas MRP1 has an additional membrane-spanning domain located at the N-terminus, called MSD0. The MSD0 functions as a plug that controls gating during drug transport (Figure 3B). Mutations at certain cysteine residues within MSD0 drastically reduce drug-transport activities. A previous study has identified that MSD0 is necessary for the dimerization of MRP1, which can be disrupted by treatment with dithiothreitol (DTT), a reducing agent. These data suggest that dimerization is formed through disulfide linkage between cysteine residues. Yang et al investigated the roles of Cys7 and Cys32, which are located in the MSD0 domain, in MRP1 dimerization (Figure 3B). Mutations at Cys7 caused conformational changes and prevented dimerization in MRP1. In addition to dimerization, cancer cells activate antioxidant systems after treatment of ROS-inducing anticancer drugs, including enhanced expression of glutathione (GSH), which can form glutathione S-conjugated molecules to facilitate drug efflux by MRP1.

8In contrast to the molecular structures of MDR1 and MRP1, BCRP comprises six transmembrane domains and only one ATP-binding cassette, and is known as a ‘half-transporter’. Human BCRP exists in the plasma membrane as a homodimer due to disulfide-bonded cysteine residues (Figure 3C). Treatment with 2-mercaptoethanol (2-ME) reduces the BCRP from homodimer to monomer. Three of the cysteine residues, Cys592, Cys 603, and Cys608 in BCRP are located on the extracellular face between TMD5 and TMD6 (Figure 3C). Cys592 and Cys608 are critical for protein stability by intramolecular disulfide bond formation. Mutations at these two cysteine residues result in protein misfolding and degradation, thereby increasing drug sensitivity because of inefficient drug elimination. Cys603 is implicated in intermolecular disulfide bond formation, resulting in dimerization of BCRP (Figure 3C). Mutation at Cys603 prevents homodimerization. However, functional analyses demonstrates that mutation at Cys603 do not change the transport activity of the drugs SN-38 and mitoxantrone, even though monomeric BCRP represents only a half-molecule of a functional ABC transporter. Recently, Cys284, Cys374, and Cys438 are also reported to be involved in intramolecular disulfide bond formation and necessary for BCRP function.

Redox determine transporter gene expression

9Apart from the conformational changes of those drug efflux pumps mentioned above, redox-induced overexpression of efflux pumps provides alternative ‘gates’ by which drugs can be exported from cells. Overexpressed transporters have been frequently observed in many types of human malignancy, and correlated with reduced response to chemotherapeutic agents. After treatment with anticancer drugs, redox signaling networks are activated to regulate these transporters expression in multiple layers, including transcriptional, translational, post-translational, and epigenetic levels.

Transcriptional regulation

10Accumulating evidence shows that redox-sensing transcription factors take part in the transcriptional regulation of drug efflux transporters (Figure 4). Nuclear factor-erythroid 2 related factor 2 (NRF2), a redox-sensing transcription factor, can bind to antioxidant response element (ARE) and regulates a broad spectrum of genes involved in redox balancing, glutathione synthesis, and drug detoxification. AREs are identified in the promoter region of efflux transporters, such as BCRP and MRPs. In general, NRF2 is anchored in the cytoplasm by Kelch-like ECH-associated protein 1 (KEAP1), which facilitates NRF2 ubiquitination and proteasomal degradation. Cys273 and Cys288 of KEAP1 are the crucial target residues for oxidation. Redox modifications dissociate KEAP1 from NRF2, allowing the translocation of NRF2 to the nucleus, where it transactivates target gene expression (Figure 4). Recent studies showed that higher levels of NRF2 could promote tumorigenesis and contribute to chemoresistance, suggesting a “dark side” of the NRF2 pathway. For example, the expression of NRF2 is increased during acquired resistance to tamoxifen and doxorubicin in breast and ovarian cancer cells. Nuclear accumulation of NRF2 can lead to enhanced expression of ARE-containing genes including drug efflux transporters, which facilitate the development of drug resistance. In addition, overexpression of NRF2 causes enhanced resistance to chemotherapeutic agents, including cisplatin, doxorubicin and etoposide. Higher expressions of NRF2 and its target genes are associated with taxol resistance and anchorage-independent growth in MCF-7 and MDA-MB-231 mammospheres compared to adherent cells. Moreover, transport activities of several MRPs are activated by γ-glutamylcysteine synthetase (γ-GCS, the rate-limiting enzyme for GSH de novo biosynthesis), which can be induced by NRF2.

11Forkhead box O (FOXO) proteins, a family of transcription factors, are deregulated in several cancers including prostate, breast, glioblastoma, rhabdomyosarcoma, and leukemia. As inactivation of FOXOs has been determined to be a crucial step in carcinogenesis, increasing their activity could be a potential therapeutic strategy for cancer treatment. FOXOs are not only responsible for the initial therapeutic response to anticancer drugs, but also involved in the acquisition of drug resistance (Figure 4). Under continuous stress induced by anticancer drugs, FOXOs can elicit the expression of relevant genes for drug efflux and antioxidant defense, such as MDR1, MRP2, Mn-SOD and catalase. For instance, FOXO3 and FOXO1 can induce MDR1 expression in adriamycin-resistant breast cancer cells and K562 leukemic cells. In addition, the promoter region of the human MRP2 gene contains four FOXO binding sites, and transcription of MRP2 gene is stimulated by overexpressed FOXO1 in MCF-7 cells. FOXO1 expression is significantly upregulated in a paclitaxel resistant cells and further enhanced by exposure to paclitaxel. Furthermore, FOXO1 overexpression has been frequently observed in cancer tissue samples obtained from chemoresistant patients. Paradoxically, recent studies showed that FOXO3 expression levels were decreased in cisplatin-resistant cells, and FOXO3 knockdown increased cell proliferation and enhanced resistance to cisplatin.

12Ataxia telangiectasia mutated (ATM) is a serine/threonine protein kinase that participates in activation of the DNA damage checkpoint, resulting in cell cycle arrest, DNA repair or apoptosis. Recent studies have revealed a novel mechanism of ATM activation via direct oxidation. When ATM is activated by double-strand breaks (DSBs), the protein undergoes monomerization that requires free DNA ends and the Mre11-Rad50-Nbs1 (MRN) complex. By contrast, when ATM is activated by direct oxidation, oxidized ATM forms an active dimer covalently linked by intermolecular disulfide bonds. Residue Cys2991 is crucial for ATM activation by oxidation. A C2991L mutant cannot be activated by H2O2 but can be normally activated by the MRN complex and DNA. A recent study showed that both camptothecin and cisplatin treatment not only induced ATM activation, but also upregulated MDR-related genes BCRP and MRP2 expression in NCI-H446 cells. Moreover, cisplatin and camptothecin-induced BCRP and MRP2 upregulation can be suppressed by ATM inhibitors, indicating the role of ATM activation on MDR formation in lung cancer chemotherapy.

Post-translational regulation

13MDR1 is a phosphorylation substrate for a number of protein kinases, including protein kinase C (PKC) and protein kinase A (PKA). PKA is shown to be activated by redox modifications through the formation of intramolecular disulfide bonds which cause a subcellular translocation, resulting in phosphorylation of established protein substrates. PKC catalytic properties can be altered by redox mechanisms, which in turn influence the activity of MDR1. Activation of PKC has been reported to increase the phosphorylation of MDR1 in multidrug-resistant cells and decrease drug accumulation and sensitivity. Conversely, treatment with PKC inhibitors has been shown to decrease the phosphorylation of MDR1, resulting in attenuated drug efflux activity and MDR1 drug binding.

Epigenetic regulation

14The promoter region of MDR1 is highly GC-rich and contains several CpG islands that are prone to be methylated for transcriptional silencing. Studies have demonstrates that the methylation status of the MDR1 promoter is correlated with MDR1 gene transcriptional activity. The methylation is catalyzed by DNA methyltransferases (DNMTs) and use of S-adenosylmethionine (SAM) as a methyl donor. SAM is the first metabolite in the methionine cycle catalyzed by S-adenosylmethionine synthetase (also known as methionine adenosyltransferase, MAT). The activities of MATs are profoundly correlated with redox conditions, through the maintenance of a homotetrameric conformation. The methionine cycle is the primary source of cysteine, a precursor of GSH in the transsulfuration pathway. Intracellular GSH levels are essential in the maintenance of methylated DNA. GSH depletion by hepatotoxin bromobenzene results in a reduction of intracellular methionine pools and genome-wide DNA hypomethylation.

ALTERED DRUG METABOLISM

15Besides increased rates of drug efflux, altered drug metabolism is another important resistance mechanism, including drug inactivation or deficient drug activation. The redox resetting induced by anticancer drugs may hinder the therapeutic effects by such mechanisms. Antioxidant systems can directly inhibit the antitumor activity of some anticancer agents, such as paclitaxel, bortezomib and radiation therapy. For example, buthionine sulphoximine (BSO) significantly increases paclitaxel cytotoxicity through ROS accumulation. Also, platinum drugs, which generate extremely high ROS levels, can be inactivated by GSH.

16Alternatively, the cellular redox state is correlated with enzymic expression required for the conversion of antimetabolites, such as 5 fluorouracil (5-FU) and methotrexate, to their most active forms. Capecitabine is a fluoropyrimidine prodrug that is converted into 5-FU by thymidinephosphorylase. The gene encoding thymidinephosphorylase can be inactivated by DNA methylation, thereby causing capecitabine resistance. These epigenetic alterations have been shown to be induced by H2O2, where DNMT1 binds more tightly to chromatin after H2O2 treatment and then alters the methylation status of CpG regions. As observed in the case of the topoisomerase inhibitor irinotecan, the inactivation by UDP glucuronosyl transferase 1 (UGT1A1) is induced by the redox-sensing NRF2-KEAP1 pathway. Epigenetic silencing can also promote drug activity, and the expression of UGT1A1 is reduced by DNA methylation of the promoter. Therefore, in this case, promoter methylation promotes irinotecan activity.

ALTERATIONS IN THE DRUG TARGETS

17Drug response and resistance are also determined by alterations in the drug target, such as mutations or changes in expression level. The deregulated or prolonged production of cellular oxidants has been linked to mutations (induced by oxidant-mediated DNA damage), as well as modification of gene expression. Thus, target alteration is more likely to happen with anticancer drugs that induce high ROS levels.

18The fluoropyrimidine 5-FU is widely used in the treatment of a variety of cancers, including colorectal, breast, and aerodigestive tract cancer. It is converted intracellularly to three active metabolites: fluorodeoxyuridinemonophosphate (FdUMP), fluorodeoxyuridinetriphosphate (FdUTP) and fluorouridine triphosphate(FUTP) (Figure 5). These active metabolites disrupt RNA synthesis and the function of thymidylate synthase (TYMS). TYMS plays a crucial role in catalyzing deoxyuridylate (dUMP) to thymidylate (dTMP), which provides the sole intracellular de novo source of dTMP. Human TYMS protein can specifically bind to its own TYMS mRNA and functions as a translational repressor. The RNA binding activity is determined by its redox state. In the presence of reducing agents, the RNA binding activity of TYMS protein is significantly enhanced. In contrast, treatment of TYMS protein with the oxidizing agent diamide inhibits RNA binding. These results demonstrate that the oxidation of TYMS, resulting in loss of translational repressor function, could lead to 5-FU resistance in cancer cells.

19Drug target changes through epigenetic events have also been shown to be involved in resistance to cytotoxic chemotherapy drugs in a range of tumor cells. Hypermethylation of the DNA promoter regions of the drug targets results in cell resistance to anticancer drugs, such as cisplatin and carboplatin. In addition, methylation of genes involved in apoptosis, including the DNA mismatch repair (MMR) gene human mutL homolog 1 (hMLH1), can occur in drug-resistant tumor models. This has led to the concept that the use of a DNA demethylating agent such as 2′-deoxy-5-azacytidine in combination with anticancer drugs may reverse this resistance mechanism.

INEFFECTIVE INDUCTION OF CELL DEATH

20Following the action of an activated drug on its cellular target, the therapeutic outcome is then determined by the next key process; the response of cancer cells to drug treatment. Generally, oxidative stress causes by anticancer drugs in turn leads to some cellular damage (e.g., DNA damage) that is tightly coupled to the induction of cell death. Nevertheless, some intrinsic redox adaptive responses can be triggered to enable the cancer cells to survive through inhibition of cell death and activation of cellular survival pathways, thus providing a mechanism of resistance to treatment with anticancer agents.

Deregulation of apoptosis

21It is well known that resistance to apoptosis is a hallmark of cancer. Thus, deregulation of apoptosis will protect cancer cells from cell death caused by drug-induced cellular damage. Cleavage of caspase-3 is known to play a central role in apoptosis. Substantial evidence reveals that the activity of caspase-3 is inhibited via redox modifications. Caspase-3 has been found to be constitutively S-glutathionylated in human umbilical vein endothelial cells (HUVECs). Upon tumor necrosis factor α (TNFα) stimulation, de-glutathionylation of caspase-3 occurs mediated by glutaredoxin (Grx). Knockdown of Grx notably inhibit TNFα-induced cell death owing to attenuated caspase-3 cleavage, concomitant with enhanced caspase-3 S-glutathionylation. Mutations of key S-glutathionylation sites of caspase-3 (C163S, C184S, and C220S) enhance cleavage compared with wild-type caspase-3. Furthermore, S-glutathionylated caspase-3 inhibits its cleavage by caspase-8 in vitro (Figure 6). In addition, caspase-3 can also be S-nitrosylated at Cys163. Upon the first apoptosis signal (Fas) ligation, de-nitrosylated caspase-3 leads to caspase-3 activation (Figure 6). Collectively, the higher ROS levels in drug-resistant cells may contribute to their escape from apoptosis by caspase-3 S-glutathionylation and S-nitrosylation.

22Upon Fas ligand (FasL) binding, Fas interacts with Fas-associated protein with death domain (FADD) and procaspase 8 or 10, to form an active death inducing signaling complex (DISC). The FADD and procaspase-8 interaction can be inhibited by Flice inhibitory protein (FLIP) through competitive binding to FADD. Intriguingly, the activity of FLIP is shown to be enhanced by S-nitrosylation. Loss of S-nitrosylation increases FLIP degradation, which in turn facilitates DISC complex formation, and results in activation of the downstream apoptosis cascade (Figure 6). FLIP have been shown to be involved in cisplatin-resistance to bladder cancer cells. Also, fibroblast growth factor receptor 4 (FGFR4) has been indicated to be an inducer of chemoresistance in colorectal cancer through regulation of FLIP expression. Thus, inhibition of FLIP may be a promising therapeutic strategy in numerous drug-resistant cancer scenarios. Taken together, these studies described herein highlight that apoptosis is deregulated at multiple layers via redox-associated mechanisms.

Activation of autophagy

23Autophagy plays paradoxical roles in acquired resistance to anticancer drugs. On one hand, cytotoxic drug treatment triggers persistent autophagy, which will produce excessive cellular damage and even lead to cell death, thus attenuating the drug resistance activity of cancer cells. On the other hand, autophagy has a role in maintaining cancer cell survival during conditions of stress and might mediate resistance to anticancer therapies. For example, co-administration of cisplatin and an autophagy inhibitor chloroquine significantly suppress tumor survival whereas cisplatin monotherapy fails to show anticancer activity in nude mice xenografts using EC109/CDDP cells. Another study demonstrated that in chronic lymphocytic leukemia (CLL), autophagy was induced by multiple stimuli and acted as a mechanism of resistance against flavopiridol, an endoplasmic reticulum (ER)-stress-mediating agent.

24Redox resetting has been shown to regulate autophagy at multiple levels. To start with, high cellular ROS accumulation has been widely proven to induce autophagy. In response to ER stress induced by tunicamycin, but not thapsigargin, NADPH oxidase 4 (Nox4)-mediated production of H2O2 leads to cytoprotective autophagy in HUVEC cells. Treatment with either the antioxidant N-acetyl-L-cysteine (NAC) or catalase hinder the conversion of LC3-I to LC3-II which is a key step in autophagy induction, thereby decreasing the formation of LC3-II positive autophagosomes, and reducing starvation-induced protein degradation. The activity of Atg4, which has been shown to be involved in the processing of LC3, has also been proved to be sensitive to H2O2. However, antioxidant activity is also essential for autophagy induction. For example, overexpression of catalase increases LC3-II levels in both HCT116 cells and H460 cells with low levels of endogenous catalase. Inhibition or knockdown of catalase attenuates LC3-II accumulation in HCT116, H1299 as well as WI38 cells. Due to the paradoxical roles autophagy plays in cancers, a better understanding of how redox regulation distinguishes between the survival-supporting and death-promoting roles of autophagy is necessary.

DNA damage repair

25The anticancer activity of most chemotherapy drugs relies on the induction of DNA damage in rapidly cycling tumor cells with inadequate DNA repair. The cellular response to DNA damage is either repair or cell death. Therefore, the DNA damage repair capacity of cancer cells has a significant influence on the efficacy of DNA-damaging drugs.

26The redox environment is capable of directly modulating DNA repair. One of the initial pieces of evidence is that both an increase in 8-oxoguanine (8-oxoG) and a reduction in DNA repair occurs in vitro following treatment with cadmium. This is subsequently shown to be due to cysteine modification of 8-oxoguanine DNA glycosylase 1 (OGG1). Furthermore, an interaction between OGG1 and poly (ADP-ribose) polymerase 1 (PARP-1), a sensor of DNA damage involved in DNA repair, has recently been described. This interaction is enhanced by oxidative stress and can stimulate PARP-1 activity. Oxidative stress also causes the translocation of the Y-box binding protein (YB-1) to the nucleus, where it has a stable interaction with nei-like 2 protein (NEIL2) and increases NEIL2 activity in the base excision repair (BER) pathway. A further example of redox regulation of DNA damage repair is the interaction between oxidized XRCC1 (x-ray cross-complementing group 1) and DNA polymerase b (Pol b) which is enhanced due to the formation of a disulfide bond.

27Apurinic-apyrimidinic endonuclease 1 (APE-1) is a versatile protein that has both DNA repair and transcriptional regulatory functions by facilitating transcription factors binding to DNA. Overexpression of APE-1 has been found in several cancers and are correlated with the tumor radiosensitivity. For example, APE-1 contributes to radioresistance and alkylating agent resistance in human glioma cells, as well as also promotes resistance to radiation combined with chemotherapy in medulloblastoma, primitive neuroectodermal tumors and pediatric ependymomas. Knockdown of APE-1 dramatically sensitizes cancer cells to radiotherapy in pancreatic carcinoma. APE-1 can be activated by nontoxic levels of ROS that promote translocation into the nucleus (Figure 4). ROS production following Ca2+ mobilization via purinergic receptors-induced extracellular ATP stimulation is responsible for the localization of APE-1. Furthermore APE-1 phosphorylation by PKC after an oxidative challenge has been shown to increase the activity of the APE-1 redox domain.

28In addition, the activities of other DNA-repair proteins such as Ku, ATM, and human replication protein A (RPA) have been also reported to be altered by the redox resetting. In the nonhomologous end joining (NHEJ) double-strand DNA repair pathway, Ku DNA binding is lower in an oxidizing environment, although the mechanism is not clear. Ku is a heterodimer that encircles broken DNA ends during repair and can recruit the DNA-PK catalytic subunit (DNA-PKcs). The duration of binding of Ku to the DNA is needed to improve recruitment of DNA-PKcs to the DNA-PK complex. Ku is inactivated during oxidative stress in glucose-6-phosphate dehydrogenase (G6PD) null mutant Chinese hamster ovary cells. ATM is subsequently activated through oxidation at specific cysteine residues. Evidence also shows that ATM can promote an antioxidant response via regulation of the pentose phosphate pathway—one of the primary sources of NADPH. An additional example of a DNA repair pathway protein involved in oxidative stress is human RPA. RPA is a DNA-binding protein involved in replication, repair, and recombination. In an oxidizing environment, the cysteines in the zinc-finger motif of the p70 subunit form disulfide bonds that impair its DNA binding.

29It has been established that the detection of MMR is associated with resistance to many, but not all, DNA-damaging anticancer agents, such as monofunctional alkylating agents, cisplatin, and the antimetabolite 6-thioguanine. Alkylating agents, including the chloroethylnitrosoureas (carmustine [BCNU], lomustine, and fotemustine), temozolomide, and procarbazine, are commonly used for the treatment of malignant brain tumors. These agents add alkyl groups to DNA causing DNA damage and apoptosis. Resistance to alkylating agents through direct DNA repair by O6-methylguanine methyltransferase (MGMT) remains a significant barrier to successful treatments of patients with malignant glioma. The relative expressions of MGMT in tumor cells may determine the response to alkylating agents. Moreover, promoter methylation can silence MGMT expression in gliomas. Recent studies showed that oxidative damage induced the formation of a large complex containing the DNMTs and polycomb repressive complex 4 (PRC4) members, which could lead to MGMT promoter methylation. Early clinical studies showed that glioma patients with methylated MGMT promoters had a survival benefit treated with radiotherapy.

TARGETING REDOX ALTERATIONS IN CANCER THERAPY

30In general, cancer cells exhibit higher levels of ROS than normal cells that facilitate tumorigenesis and tumor progression. Therefore, the treatment of antioxidants can suppress cancer initiation or progression. A number of studies suggest that antioxidants could diminish cancer initiation by suppressing DNA damage and genomic instability. For example, ATM-deficiency-accelerated transgenic murine lymphomagenesis is suppressible by NAC. Another study has also claimed that NAC slowed tumor progression in a p53-dependent mouse lymphomagenesis model, seemingly by reducing genomic instability. Furthermore, a recent study has also observed that NAC and vitamin C have significant antitumorigenic effects in vivo. But in stark contrast to earlier studies, they found that the effect of NAC and vitamin C highly relied on hypoxia-inducible factor 1 (HIF-1) rather than on reduction of genomic instability in a MYC-dependent lymphoma model. However, other studies showed that supplementation with vitamin E significantly increased the risk of prostate cancer and taking b-carotene, vitamin A or E supplements increased the incidence of lung cancer. A recent study showing that NAC promotes melanoma progression supports these findings. Likewise, a study showed that NAC increased melanoma metastasis in vivo through the small guanosine triphosphatase (GTPase) RHOA activation.

31Based on the intrinsic oxidative stress of cancer cells, further ROS inductions have been shown to be efficient in preferentially killing malignant cells, with some showing promise in clinical studies. However, upregulated antioxidant capacity has been found in some cancer cells, especially those in advanced stages. This redox adaptation enables the cancer cells to survive under increased oxidative stress, and provides a mechanism of drug resistance. For example, elevated levels and activity of catalase are found in multidrug resistant HL-60 leukaemia cells. Upregulation of HMOX1, SOD1 and GSH are found to be associated with arsenic trioxide resistance. Also, several studies suggest that the resistance to doxorubicin, paclitaxel or platinum-based drugs, which induce intracellular ROS production, is correlated with increased antioxidant capacity.

32For those cancer cells that have adapted to higher level of oxidative stress by increasing their antioxidant capacity, simply ROS-generating agents treatment might not be effective. It is possible to combine ROS-generating drugs with compounds that restrain the cellular antioxidant capacity. For example, a combination of arsenic trioxide and 2-Me, a SOD inhibitor, shows significantly enhanced cytotoxic activity in primary chronic lymphocytic leukaemia (CLL) cells. A combination of arsenic trioxide and ascorbic acid, mediating GSH depletion, are also reported to be effective for relapsed or refractory multiple myeloma in a clinical study.

CONCLUSIONS

33Due to significant advances in the research arena in the last few decades, cancer drug resistance is now realized to be more complicated than originally conceived. The emergence of drug resistance is the result of dynamic battles between cancer cells and chemotherapeutic agents. Although new anticancer drugs will continue to be developed, it is anticipated that novel drug-resistance mechanisms will follow. Therefore, deciphering the intrinsic mechanisms of drug resistance induction may be an effective strategy to solve this significant problem in cancer therapy.

34Redox resetting, which usually occurs in anticancer drug treatment, is a protective response from tumor cells that can buffer drug-induced stresses and damage by rebuilding redox homeostasis and activating multiple redox signaling pathways, thereby leading to drug resistance. The versatility of redox signaling is such that it can affect almost every cell and involve multiple signaling processes. Thus it is anticipated that redox signaling will continue to be an important stimulator in the development of drug resistance with new therapeutic agents. Therefore, it is essential to reveal and understand the molecular mechanisms underlying redox resetting-induced drug resistance.

35Despite the universality of redox resetting in chemotherapeutic treatments, different agents for distinct cancer types, patients with individual variations, and genetic heterogeneity in tumors may lead to inequable situations. Therefore, only when we have screened and identified enough usable drug-resistant biomarkers related to redox resetting, will it be feasible to overcome drug resistance by monitoring and regulating the process of redox resetting. The use of modern genomic, proteomic and other omics techniques has dramatically promoted the ability to identify novel genes and signaling networks involved in tumor responsiveness to drug treatment. Moreover, high-throughput techniques combined with bioinformatics approaches has allowed the identification of genotypes and molecular signatures also aided the interrogation of clinical samples, facilitating the prediction of drug responses to certain drugs. These will provide abundant data that can be used to identify potential predictive biomarkers for patient stratification.

References 198

1.
Holohan C, Van Schaeybroeck S, Longley DB, Johnston PG. Cancer drug resistance: an evolving paradigm. Nature reviews Cancer. 2013;13:714-726.
Not in our library10.1038/nrc3599
2.
Kuczynski EA, Sargent DJ, Grothey A, Kerbel RS. Drug rechallenge and treatment beyond progression—implications for drug resistance. Nature reviews Clinical oncology. 2013;10:571-587.
Not in our library10.1038/nrclinonc.2013.158
3.
Bock C, Lengauer T. Managing drug resistance in cancer: lessons from HIV therapy. Nature reviews Cancer. 2012;12:494-501.
Not in our library10.1038/nrc3297
4.
Tanaka H, Matsumura I, Ezoe S, Satoh Y, Sakamaki T, Albanese C, Machii T, Pestell RG, Kanakura Y. E2F1 and c-Myc potentiate apoptosis through inhibition of NF-kappaB activity that facilitates MnSOD-mediated ROS elimination. Molecular cell. 2002;9:1017-1029.
Not in our library10.1016/s1097-2765(02)00522-1
5.
Gorrini C, Harris IS, Mak TW. Modulation of oxidative stress as an anticancer strategy. Nature reviews Drug discovery. 2013;12:931-947.
Not in our library10.1038/nrd4002
6.
Nathan C, Cunningham-Bussel A. Beyond oxidative stress: an immunologist's guide to reactive oxygen species. Nature reviews Immunology. 2013;13:349-361.
Not in our library10.1038/nri3423
7.
Trachootham D, Alexandre J, Huang P. Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach? Nature reviews Drug discovery. 2009;8:579-591.
Not in our library10.1038/nrd2803
8.
Role of Glutathione in Cancer Progression and Chemoresistance · 2013
No notice
9.
Tew KD, O'Brien M, Laing NM, Shen H. Coordinate changes in expression of protective genes in drug-resistant cells. Chemico-biological interactions. 1998;111-112:199-211.
Not in our library10.1016/s0009-2797(97)00162-2
10.
Gottesman MM, Fojo T, Bates SE. Multidrug resistance in cancer: role of ATP-dependent transporters. Nature reviews Cancer. 2002;2:48-58.
Not in our library10.1038/nrc706
11.
Borst P, Elferink RO. Mammalian ABC transporters in health and disease. Annual review of biochemistry. 2002;71:537-592.
Not in our library10.1146/annurev.biochem.71.102301.093055
12.
Debatin KM, Krammer PH. Death receptors in chemotherapy and cancer. Oncogene. 2004;23:2950-2966.
Not in our library10.1038/sj.onc.1207558
13.
Lowe SW, Cepero E, Evan G. Intrinsic tumour suppression. Nature. 2004;432:307-315.
Not in our library10.1038/nature03098
14.
Wong K, Ma J, Rothnie A, Biggin PC, Kerr ID. Towards understanding promiscuity in multidrug efflux pumps. Trends in biochemical sciences. 2014;39:8-16.
Not in our library10.1016/j.tibs.2013.11.002
15.
Higgins CF, Hiles ID, Salmond GP, Gill DR, Downie JA, Evans IJ, Holland IB, Gray L, Buckel SD, Bell AW, Hermodsend MA. A family of related ATP-binding subunits coupled to many distinct biological processes in bacteria. Nature. 1986;323:448-450.
Not in our library10.1038/323448a0
16.
Higgins CF. Multiple molecular mechanisms for multidrug resistance transporters. Nature. 2007;446:749-757.
Not in our library10.1038/nature05630
17.
Hohl M, Briand C, Grutter MG, Seeger MA. Crystal structure of a heterodimeric ABC transporter in its inward-facing conformation. Nature structural & molecular biology. 2012;19:395-402.
Not in our library10.1038/nsmb.2267
18.
Loo TW, Clarke DM. Covalent modification of human P-glycoprotein mutants containing a single cysteine in either nucleotide-binding fold abolishes drug-stimulated ATPase activity. The Journal of biological chemistry. 1995;270:22957-22961.
Not in our library10.1074/jbc.270.39.22957
19.
Jin MS, Oldham ML, Zhang Q, Chen J. Crystal structure of the multidrug transporter P-glycoprotein from Caenorhabditis elegans. Nature. 2012;490:566-569.
Not in our library10.1038/nature11448
20.
Cole SP. Targeting multidrug resistance protein 1 (MRP1, ABCC1): past, present, and future. Annual review of pharmacology and toxicology. 2014;54:95-117.
Not in our library10.1146/annurev-pharmtox-011613-135959
21.
Chen Q, Yang Y, Li L, Zhang JT. The amino terminus of the human multidrug resistance transporter ABCC1 has a U-shaped folding with a gating function. The Journal of biological chemistry. 2006;281:31152-31163.
Not in our library10.1074/jbc.m603529200
22.
Leslie EM, Letourneau IJ, Deeley RG, Cole SP. Functional and structural consequences of cysteine substitutions in the NH2 proximal region of the human multidrug resistance protein 1 (MRP1/ABCC1). Biochemistry. 2003;42:5214-5224.
Not in our library10.1021/bi027076n
23.
Yang Y, Chen Q, Zhang JT. Structural and functional consequences of mutating cysteine residues in the amino terminus of human multidrug resistance-associated protein 1. The Journal of biological chemistry. 2002;277:44268-44277.
Not in our library10.1074/jbc.m207003200
24.
Yang Y, Liu Y, Dong Z, Xu J, Peng H, Liu Z, Zhang JT. Regulation of function by dimerization through the amino-terminal membrane-spanning domain of human ABCC1/MRP1. The Journal of biological chemistry. 2007;282:8821-8830.
Not in our library10.1074/jbc.m700152200
25.
Yang Y, Li Z, Mo W, Ambadipudi R, Arnold RJ, Hrncirova P, Novotny MV, Georges E, Zhang JT. Human ABCC1 interacts and colocalizes with ATP synthase alpha, revealed by interactive proteomics analysis. Journal of proteome research. 2012;11:1364-1372.
Not in our library10.1021/pr201003g
26.
Maiti AK. Genetic determinants of oxidative stress-mediated sensitization of drug-resistant cancer cells. International journal of cancer. 2012;130:1-9.
Not in our library10.1002/ijc.26306
27.
Krause MS, Oliveira LP, Silveira EM, Vianna DR, Rossato JS, Almeida BS, Rodrigues MF, Fernandes AJ, Costa JA, Curi R, de Bittencourt PI. MRP1/GS-X pump ATPase expression: is this the explanation for the cytoprotection of the heart against oxidative stress-induced redox imbalance in comparison to skeletal muscle cells? Cell biochemistry and function. 2007;25:23-32.
Not in our library10.1002/cbf.1343
28.
Mo W, Zhang JT. Human ABCG2: structure, function, and its role in multidrug resistance. International journal of biochemistry and molecular biology. 2012;3:1-27.
Not in our library
29.
Wakabayashi K, Tamura A, Saito H, Onishi Y, Ishikawa T. Human ABC transporter ABCG2 in xenobiotic protection and redox biology. Drug metabolism reviews. 2006;38:371-391.
Not in our library10.1080/03602530600727947
30.
Mitomo H, Kato R, Ito A, Kasamatsu S, Ikegami Y, Kii I, Kudo A, Kobatake E, Sumino Y, Ishikawa T. A functional study on polymorphism of the ATP-binding cassette transporter ABCG2: critical role of arginine-482 in methotrexate transport. The Biochemical journal. 2003;373:767-774.
Not in our library10.1042/bj20030150
31.
Henriksen U, Fog JU, Litman T, Gether U. Identification of intra- and intermolecular disulfide bridges in the multidrug resistance transporter ABCG2. The Journal of biological chemistry. 2005;280:36926-36934.
Not in our library10.1074/jbc.m502937200
32.
Kage K, Fujita T, Sugimoto Y. Role of Cys-603 in dimer/oligomer formation of the breast cancer resistance protein BCRP/ABCG2. Cancer science. 2005;96:866-872.
Not in our library10.1111/j.1349-7006.2005.00126.x
33.
Wakabayashi K, Nakagawa H, Adachi T, Kii I, Kobatake E, Kudo A, Ishikawa T. Identification of cysteine residues critically involved in homodimer formation and protein expression of human ATP-binding cassette transporter ABCG2: a new approach using the flp recombinase system. Journal of experimental therapeutics & oncology. 2006;5:205-222.
Not in our library
34.
Liu Y, Yang Y, Qi J, Peng H, Zhang JT. Effect of cysteine mutagenesis on the function and disulfide bond formation of human ABCG2. The Journal of pharmacology and experimental therapeutics. 2008;326:33-40.
Not in our library10.1124/jpet.108.138115
35.
Thomas H, Coley HM. Overcoming multidrug resistance in cancer: an update on the clinical strategy of inhibiting p-glycoprotein. Cancer control. 2003;10:159-165.
Not in our library10.1177/107327480301000207
36.
Singh A, Wu H, Zhang P, Happel C, Ma J, Biswal S. Expression of ABCG2 (BCRP) is regulated by Nrf2 in cancer cells that confers side population and chemoresistance phenotype. Molecular cancer therapeutics. 2010;9:2365-2376.
Not in our library10.1158/1535-7163.mct-10-0108
37.
Dinkova-Kostova AT, Holtzclaw WD, Cole RN, Itoh K, Wakabayashi N, Katoh Y, Yamamoto M, Talalay P. Direct evidence that sulfhydryl groups of Keap1 are the sensors regulating induction of phase 2 enzymes that protect against carcinogens and oxidants. Proceedings of the National Academy of Sciences of the United States of America. 2002;99:11908-11913.
Not in our library10.1073/pnas.172398899
38.
Hayes JD, McMahon M. The double-edged sword of Nrf2: subversion of redox homeostasis during the evolution of cancer. Molecular cell. 2006;21:732-734.
Not in our library10.1016/j.molcel.2006.03.004
39.
Lau A, Villeneuve NF, Sun Z, Wong PK, Zhang DD. Dual roles of Nrf2 in cancer. Pharmacological research. 2008;58:262-270.
Not in our library10.1016/j.phrs.2008.09.003
40.
Wang XJ, Sun Z, Villeneuve NF, Zhang S, Zhao F, Li Y, Chen W, Yi X, Zheng W, Wondrak GT, Wong PK, Zhang DD. Nrf2 enhances resistance of cancer cells to chemotherapeutic drugs, the dark side of Nrf2. Carcinogenesis. 2008;29:1235-1243.
Not in our library10.1093/carcin/bgn095
41.
Kensler TW, Wakabayashi N. Nrf2: friend or foe for chemoprevention? Carcinogenesis. 2010;31:90-99.
Not in our library10.1093/carcin/bgp231
42.
Ganan-Gomez I, Wei Y, Yang H, Boyano-Adanez MC, Garcia-Manero G. Oncogenic functions of the transcription factor Nrf2. Free radical biology & medicine. 2013;65:750-764.
Not in our library10.1016/j.freeradbiomed.2013.06.041
43.
Sporn MB, Liby KT. NRF2 and cancer: the good, the bad and the importance of context. Nature reviews Cancer. 2012;12:564-571.
Not in our library10.1038/nrc3278
44.
Kim SK, Yang JW, Kim MR, Roh SH, Kim HG, Lee KY, Jeong HG, Kang KW. Increased expression of Nrf2/ARE-dependent anti-oxidant proteins in tamoxifen-resistant breast cancer cells. Free radical biology & medicine. 2008;45:537-546.
Not in our library10.1016/j.freeradbiomed.2008.05.011
45.
Kaspar JW, Niture SK, Jaiswal AK. Nrf2:INrf2 (Keap1) signaling in oxidative stress. Free radical biology & medicine. 2009;47:1304-1309.
Not in our library10.1016/j.freeradbiomed.2009.07.035
46.
Meijerman I, Beijnen JH, Schellens JH. Combined action and regulation of phase II enzymes and multidrug resistance proteins in multidrug resistance in cancer. Cancer treatment reviews. 2008;34:505-520.
Not in our library10.1016/j.ctrv.2008.03.002
47.
Wu T, Harder BG, Wong PK, Lang JE, Zhang DD. Oxidative stress, mammospheres and Nrf2-new implication for breast cancer therapy? Molecular carcinogenesis. 2014.
Not in our library10.1002/mc.22202
48.
Glasauer A, Chandel NS. Targeting antioxidants for cancer therapy. Biochemical pharmacology. 2014;92:90-101.
Not in our library10.1016/j.bcp.2014.07.017
49.
Myatt SS, Lam EW. The emerging roles of forkhead box (Fox) proteins in cancer. Nature reviews Cancer. 2007;7:847-859.
Not in our library10.1038/nrc2223
50.
Yang JY, Hung MC. A new fork for clinical application: targeting forkhead transcription factors in cancer. Clinical cancer research. 2009;15:752-757.
Not in our library10.1158/1078-0432.ccr-08-0124
51.
Zhang Y, Gan B, Liu D, Paik JH. FoxO family members in cancer. Cancer biology & therapy. 2011;12:253-259.
Not in our library10.4161/cbt.12.4.15954
52.
Gomes AR, Zhao F, Lam EW. Role and regulation of the forkhead transcription factors FOXO3a and FOXM1 in carcinogenesis and drug resistance. Chinese journal of cancer. 2013;32:365-370.
Not in our library10.5732/cjc.012.10277
53.
Choi HK, Cho KB, Phuong NT, Han CY, Han HK, Hien TT, Choi HS, Kang KW. SIRT1-mediated FoxO1 deacetylation is essential for multidrug resistance-associated protein 2 expression in tamoxifen-resistant breast cancer cells. Molecular pharmaceutics. 2013;10:2517-2527.
Not in our library10.1021/mp400287p
54.
Han CY, Cho KB, Choi HS, Han HK, Kang KW. Role of FoxO1 activation in MDR1 expression in adriamycin-resistant breast cancer cells. Carcinogenesis. 2008;29:1837-1844.
Not in our library10.1093/carcin/bgn092
55.
Putker M, Madl T, Vos HR, de Ruiter H, Visscher M, van den Berg MC, Kaplan M, Korswagen HC, Boelens R, Vermeulen M, Burgering BM, Dansen TB. Redox-dependent control of FOXO/DAF-16 by transportin-1. Molecular cell. 2013;49:730-742.
Not in our library10.1016/j.molcel.2012.12.014
56.
Wang J, Yang H, Li W, Xu H, Yang X, Gan L. Thioredoxin 1 upregulates FOXO1 transcriptional activity in drug resistance in ovarian cancer cells. Biochimica et biophysica acta. 2015;1852:395-405.
Not in our library10.1016/j.bbadis.2014.12.002
57.
Goto T, Takano M. Transcriptional role of FOXO1 in drug resistance through antioxidant defense systems. Advances in experimental medicine and biology. 2009;665:171-179.
Not in our library10.1007/978-1-4419-1599-3_13
58.
Tezil T, Bodur C, Kutuk O, Basaga H. IKK-beta mediates chemoresistance by sequestering FOXO3; a critical factor for cell survival and death. Cellular signalling. 2012;24:1361-1368.
Not in our library10.1016/j.cellsig.2012.01.012
59.
Shiota M, Yokomizo A, Kashiwagi E, Tada Y, Inokuchi J, Tatsugami K, Kuroiwa K, Uchiumi T, Seki N, Naito S. Foxo3a expression and acetylation regulate cancer cell growth and sensitivity to cisplatin. Cancer science. 2010;101:1177-1185.
Not in our library10.1111/j.1349-7006.2010.01503.x
60.
Shiloh Y, Ziv Y. The ATM protein kinase: regulating the cellular response to genotoxic stress, and more. Nature reviews Molecular cell biology. 2013;14:197-210.
Not in our library
61.
Guo Z, Kozlov S, Lavin MF, Person MD, Paull TT. ATM activation by oxidative stress. Science. 2010;330:517-521.
Not in our library10.1126/science.1192912
62.
Guo Z, Deshpande R, Paull TT. ATM activation in the presence of oxidative stress. Cell cycle. 2010;9:4805-4811.
Not in our library10.4161/cc.9.24.14323
63.
Ke SZ, Ni XY, Zhang YH, Wang YN, Wu B, Gao FG. Camptothecin and cisplatin upregulate ABCG2 and MRP2 expression by activating the ATM/NF-kappaB pathway in lung cancer cells. International journal of oncology. 2013;42:1289-1296.
Not in our library10.3892/ijo.2013.1805
64.
Mellado W, Horwitz SB. Phosphorylation of the multidrug resistance associated glycoprotein. Biochemistry. 1987;26:6900-6904.
Not in our library10.1021/bi00396a005
65.
Brennan JP, Bardswell SC, Burgoyne JR, Fuller W, Schroder E, Wait R, Begum S, Kentish JC, Eaton P. Oxidant-induced activation of type I protein kinase A is mediated by RI subunit interprotein disulfide bond formation. The Journal of biological chemistry. 2006;281:21827-21836.
Not in our library10.1074/jbc.m603952200
66.
Giorgi C, Agnoletto C, Baldini C, Bononi A, Bonora M, Marchi S, Missiroli S, Patergnani S, Poletti F, Rimessi A, Zavan B, Pinton P. Redox control of protein kinase C: cell- and disease-specific aspects. Antioxidants & redox signaling. 2010;13:1051-1085.
Not in our library10.1089/ars.2009.2825
67.
Blobe GC, Sachs CW, Khan WA, Fabbro D, Stabel S, Wetsel WC, Obeid LM, Fine RL, Hannun YA. Selective regulation of expression of protein kinase C (PKC) isoenzymes in multidrug-resistant MCF-7 cells. Functional significance of enhanced expression of PKC alpha. The Journal of biological chemistry. 1993;268:658-664.
Not in our library
68.
Bates SE, Lee JS, Dickstein B, Spolyar M, Fojo AT. Differential modulation of P-glycoprotein transport by protein kinase inhibition. Biochemistry. 1993;32:9156-9164.
Not in our library10.1021/bi00086a022
69.
Vanoye CG, Castro AF, Pourcher T, Reuss L, Altenberg GA. Phosphorylation of P-glycoprotein by PKA and PKC modulates swelling-activated Cl- currents. The American journal of physiology. 1999;276:C370-378.
Not in our library10.1152/ajpcell.1999.276.2.c370
70.
Chen M, Xue X, Wang F, An Y, Tang D, Xu Y, Wang H, Yuan Z, Gao W, Wei J, Zhang J, Miao Y. Expression and promoter methylation analysis of ATP-binding cassette genes in pancreatic cancer. Oncology reports. 2012;27:265-269.
Not in our library10.3892/or.2011.1475
71.
Baker EK, El-Osta A. MDR1, chemotherapy and chromatin remodeling. Cancer biology & therapy. 2004;3:819-824.
Not in our library10.4161/cbt.3.9.1101
72.
Baker EK, Johnstone RW, Zalcberg JR, El-Osta A. Epigenetic changes to the MDR1 locus in response to chemotherapeutic drugs. Oncogene. 2005;24:8061-8075.
Not in our library10.1038/sj.onc.1208955
73.
Elremaly W, Rouleau T, Lavoie JC. Inhibition of hepatic methionine adenosyltransferase by peroxides contaminating parenteral nutrition leads to a lower level of glutathione in newborn Guinea pigs. Free radical biology & medicine. 2012;53:2250-2255.
Not in our library10.1016/j.freeradbiomed.2012.10.541
74.
Lertratanangkoon K, Wu CJ, Savaraj N, Thomas ML. Alterations of DNA methylation by glutathione depletion. Cancer letters. 1997;120:149-156.
Not in our library10.1016/s0304-3835(97)00300-5
75.
Alexandre J, Batteux F, Nicco C, Chereau C, Laurent A, Guillevin L, Weill B, Goldwasser F. Accumulation of hydrogen peroxide is an early and crucial step for paclitaxel-induced cancer cell death both in vitro and in vivo. International journal of cancer. 2006;119:41-48.
Not in our library10.1002/ijc.21685
76.
Llobet D, Eritja N, Encinas M, Sorolla A, Yeramian A, Schoenenberger JA, Llombart-Cussac A, Marti RM, Matias-Guiu X, Dolcet X. Antioxidants block proteasome inhibitor function in endometrial carcinoma cells. Anti-cancer drugs. 2008;19:115-124.
Not in our library10.1097/cad.0b013e3282f24031
77.
Bairati I, Meyer F, Gelinas M, Fortin A, Nabid A, Brochet F, Mercier JP, Tetu B, Harel F, Abdous B, Vigneault E, Vass S, Del Vecchio P, Roy J. Randomized trial of antioxidant vitamins to prevent acute adverse effects of radiation therapy in head and neck cancer patients. Journal of clinical oncology. 2005;23:5805-5813.
Not in our library10.1200/jco.2005.05.514
78.
Meijer C, Mulder NH, Timmer-Bosscha H, Sluiter WJ, Meersma GJ, de Vries EG. Relationship of cellular glutathione to the cytotoxicity and resistance of seven platinum compounds. Cancer research. 1992;52:6885-6889.
Not in our library
79.
Schwartz PM, Moir RD, Hyde CM, Turek PJ, Handschumacher RE. Role of uridine phosphorylase in the anabolism of 5-fluorouracil. Biochemical pharmacology. 1985;34:3585-3589.
Not in our library10.1016/0006-2952(85)90737-3
80.
Houghton JA, Houghton PJ. Elucidation of pathways of 5-fluorouracil metabolism in xenografts of human colorectal adenocarcinoma. European journal of cancer & clinical oncology. 1983;19:807-815.
Not in our library10.1016/0277-5379(83)90013-5
81.
Malet-Martino M, Martino R. Clinical studies of three oral prodrugs of 5-fluorouracil (capecitabine, UFT, S-1): a review. The oncologist. 2002;7:288-323.
Not in our library10.1634/theoncologist.7-4-288
82.
Kosuri KV, Wu X, Wang L, Villalona-Calero MA, Otterson GA. An epigenetic mechanism for capecitabine resistance in mesothelioma. Biochemical and biophysical research communications. 2010;391:1465-1470.
Not in our library10.1016/j.bbrc.2009.12.095
83.
O'Hagan HM, Wang W, Sen S, Destefano Shields C, Lee SS, Zhang YW, Clements EG, Cai Y, Van Neste L, Easwaran H, Casero RA, Sears CL, Baylin SB. Oxidative damage targets complexes containing DNA methyltransferases, SIRT1, and polycomb members to promoter CpG Islands. Cancer cell. 2011;20:606-619.
Not in our library10.1016/j.ccr.2011.09.012
84.
Yueh MF, Tukey RH. Nrf2-Keap1 signaling pathway regulates human UGT1A1 expression in vitro and in transgenic UGT1 mice. The Journal of biological chemistry. 2007;282:8749-8758.
Not in our library10.1074/jbc.m610790200
85.
Belanger AS, Tojcic J, Harvey M, Guillemette C. Regulation of UGT1A1 and HNF1 transcription factor gene expression by DNA methylation in colon cancer cells. BMC molecular biology. 2010;11:9.
Not in our library10.1186/1471-2199-11-9
86.
Toffoli G, Cecchin E, Gasparini G, D'Andrea M, Azzarello G, Basso U, Mini E, Pessa S, De Mattia E, Lo Re G, Buonadonna A, Nobili S, De Paoli P, Innocenti F. Genotype-driven phase I study of irinotecan administered in combination with fluorouracil/leucovorin in patients with metastatic colorectal cancer. Journal of clinical oncology. 2010;28:866-871.
Not in our library10.1200/jco.2009.23.6125
87.
Klaunig JE, Kamendulis LM. The role of oxidative stress in carcinogenesis. Annual review of pharmacology and toxicology. 2004;44:239-267.
Not in our library10.1146/annurev.pharmtox.44.101802.121851
88.
Longley DB, Harkin DP, Johnston PG. 5-fluorouracil: mechanisms of action and clinical strategies. Nature reviews Cancer. 2003;3:330-338.
Not in our library10.1038/nrc1074
89.
Field MS, Kamynina E, Watkins D, Rosenblatt DS, Stover PJ. Human mutations in methylenetetrahydrofolate dehydrogenase 1 impair nuclear de novo thymidylate biosynthesis. Proceedings of the National Academy of Sciences of the United States of America. 2015;112:400-405.
Not in our library10.1073/pnas.1414555112
90.
Lin X, Liu J, Maley F, Chu E. Role of cysteine amino acid residues on the RNA binding activity of human thymidylate synthase. Nucleic acids research. 2003;31:4882-4887.
Not in our library10.1093/nar/gkg678
91.
Chang X, Monitto CL, Demokan S, Kim MS, Chang SS, Zhong X, Califano JA, Sidransky D. Identification of hypermethylated genes associated with cisplatin resistance in human cancers. Cancer research. 2010;70:2870-2879.
Not in our library10.1158/0008-5472.can-09-3427
92.
Stewart DJ. Mechanisms of resistance to cisplatin and carboplatin. Critical reviews in oncology/hematology. 2007;63:12-31.
Not in our library10.1016/j.critrevonc.2007.02.001
93.
Plumb JA, Strathdee G, Sludden J, Kaye SB, Brown R. Reversal of drug resistance in human tumor xenografts by 2′-deoxy-5-azacytidine-induced demethylation of the hMLH1 gene promoter. Cancer research. 2000;60:6039-6044.
Not in our library
94.
Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646-674.
Not in our library10.1016/j.cell.2011.02.013
95.
Baker A, Santos BD, Powis G. Redox control of caspase-3 activity by thioredoxin and other reduced proteins. Biochemical and biophysical research communications. 2000;268:78-81.
Not in our library10.1006/bbrc.1999.1908
96.
Anathy V, Roberson EC, Guala AS, Godburn KE, Budd RC, Janssen-Heininger YM. Redox-based regulation of apoptosis: S-glutathionylation as a regulatory mechanism to control cell death. Antioxidants & redox signaling. 2012;16:496-505.
Not in our library10.1089/ars.2011.4281
97.
Pan S, Berk BC. Glutathiolation regulates tumor necrosis factor-alpha-induced caspase-3 cleavage and apoptosis: key role for glutaredoxin in the death pathway. Circulation research. 2007;100:213-219.
Not in our library10.1161/01.res.0000256089.30318.20
98.
Mitchell DA, Marletta MA. Thioredoxin catalyzes the S-nitrosation of the caspase-3 active site cysteine. Nature chemical biology. 2005;1:154-158.
Not in our library10.1038/nchembio720
99.
Mannick JB, Hausladen A, Liu L, Hess DT, Zeng M, Miao QX, Kane LS, Gow AJ, Stamler JS. Fas-induced caspase denitrosylation. Science. 1999;284:651-654.
Not in our library10.1126/science.284.5414.651
100.
Hengartner MO. The biochemistry of apoptosis. Nature. 2000;407:770-776.
Not in our library10.1038/35037710
101.
Peter ME, Budd RC, Desbarats J, Hedrick SM, Hueber AO, Newell MK, Owen LB, Pope RM, Tschopp J, Wajant H, Wallach D, Wiltrout RH, Zornig M, Lynch DH. The CD95 receptor: apoptosis revisited. Cell. 2007;129:447-450.
Not in our library10.1016/j.cell.2007.04.031
102.
Wang L, Azad N, Kongkaneramit L, Chen F, Lu Y, Jiang BH, Rojanasakul Y. The Fas death signaling pathway connecting reactive oxygen species generation and FLICE inhibitory protein down-regulation. Journal of immunology. 2008;180:3072-3080.
Not in our library10.4049/jimmunol.180.5.3072
103.
Lee S, Yoon CY, Byun SS, Lee E, Lee SE. The role of c-FLIP in cisplatin resistance of human bladder cancer cells. The Journal of urology. 2013;189:2327-2334.
Not in our library10.1016/j.juro.2013.01.003
104.
Turkington RC, Longley DB, Allen WL, Stevenson L, McLaughlin K, Dunne PD, Blayney JK, Salto-Tellez M, Van Schaeybroeck S, Johnston PG. Fibroblast growth factor receptor 4 (FGFR4): a targetable regulator of drug resistance in colorectal cancer. Cell Death Dis. 2014;5:e1046.
Not in our library10.1038/cddis.2014.10
105.
Wilson TR, McEwan M, McLaughlin K, Le Clorennec C, Allen WL, Fennell DA, Johnston PG, Longley DB. Combined inhibition of FLIP and XIAP induces Bax-independent apoptosis in type II colorectal cancer cells. Oncogene. 2009;28:63-72.
Not in our library10.1038/onc.2008.366
106.
Kopetz S, Lesslie DP, Dallas NA, Park SI, Johnson M, Parikh NU, Kim MP, Abbruzzese JL, Ellis LM, Chandra J, Gallick GE. Synergistic activity of the SRC family kinase inhibitor dasatinib and oxaliplatin in colon carcinoma cells is mediated by oxidative stress. Cancer research. 2009;69:3842-3849.
Not in our library10.1158/0008-5472.can-08-2246
107.
Liu L, Yang M, Kang R, Wang Z, Zhao Y, Yu Y, Xie M, Yin X, Livesey KM, Loze MT, Tang D, Cao L. DAMP-mediated autophagy contributes to drug resistance. Autophagy. 2011;7:112-114.
Not in our library10.4161/auto.7.1.14005
108.
Friesen C, Fulda S, Debatin KM. Induction of CD95 ligand and apoptosis by doxorubicin is modulated by the redox state in chemosensitive- and drug-resistant tumor cells. Cell death and differentiation. 1999;6:471-480.
Not in our library10.1038/sj.cdd.4400512
109.
Hayes JD, Pulford DJ. The glutathione S-transferase supergene family: regulation of GST and the contribution of the isoenzymes to cancer chemoprotection and drug resistance. Critical reviews in biochemistry and molecular biology. 1995;30:445-600.
Not in our library10.3109/10409239509083491
110.
T Mahoney E, Byrd JC, Johnson AJ. Autophagy and ER stress play an essential role in the mechanism of action and drug resistance of the cyclin-dependent kinase inhibitor flavopiridol. Autophagy. 2013;9:434-435.
Not in our library10.4161/auto.23027
111.
Scherz-Shouval R, Elazar Z. Regulation of autophagy by ROS: physiology and pathology. Trends in biochemical sciences. 2011;36:30-38.
Not in our library10.1016/j.tibs.2010.07.007
112.
Wu RF, Ma Z, Liu Z, Terada LS. Nox4-derived H2O2 mediates endoplasmic reticulum signaling through local Ras activation. Molecular and cellular biology. 2010;30:3553-3568.
Not in our library10.1128/mcb.01445-09
113.
Scherz-Shouval R, Shvets E, Fass E, Shorer H, Gil L, Elazar Z. Reactive oxygen species are essential for autophagy and specifically regulate the activity of Atg4. The EMBO journal. 2007;26:1749-1760.
Not in our library10.1038/sj.emboj.7601623
114.
Oh SH, Kim YS, Lim SC, Hou YF, Chang IY, You HJ. Dihydrocapsaicin (DHC), a saturated structural analog of capsaicin, induces autophagy in human cancer cells in a catalase-regulated manner. Autophagy. 2008;4:1009-1019.
Not in our library10.4161/auto.6886
115.
Choi CH, Jung YK, Oh SH. Selective induction of catalase-mediated autophagy by dihydrocapsaicin in lung cell lines. Free radical biology & medicine. 2010;49:245-257.
Not in our library10.1016/j.freeradbiomed.2010.04.014
116.
Kim Y, Sun H. Functional genomic approach to identify novel genes involved in the regulation of oxidative stress resistance and animal lifespan. Aging cell. 2007;6:489-503.
Not in our library10.1111/j.1474-9726.2007.00302.x
117.
Bouwman P, Jonkers J. The effects of deregulated DNA damage signalling on cancer chemotherapy response and resistance. Nature reviews Cancer. 2012;12:587-598.
Not in our library10.1038/nrc3342
118.
Dally H, Hartwig A. Induction and repair inhibition of oxidative DNA damage by nickel(II) and cadmium(II) in mammalian cells. Carcinogenesis. 1997;18:1021-1026.
Not in our library10.1093/carcin/18.5.1021
119.
Bravard A, Vacher M, Gouget B, Coutant A, de Boisferon FH, Marsin S, Chevillard S, Radicella JP. Redox regulation of human OGG1 activity in response to cellular oxidative stress. Molecular and cellular biology. 2006;26:7430-7436.
Not in our library10.1128/mcb.00624-06
120.
Noren Hooten N, Kompaniez K, Barnes J, Lohani A, Evans MK. Poly(ADP-ribose) polymerase 1 (PARP-1) binds to 8-oxoguanine-DNA glycosylase (OGG1). The Journal of biological chemistry. 2011;286:44679-44690.
Not in our library10.1074/jbc.m111.255869
121.
Das S, Chattopadhyay R, Bhakat KK, Boldogh I, Kohno K, Prasad R, Wilson SH, Hazra TK. Stimulation of NEIL2-mediated oxidized base excision repair via YB-1 interaction during oxidative stress. The Journal of biological chemistry. 2007;282:28474-28484.
Not in our library10.1074/jbc.m704672200
122.
Cuneo MJ, London RE. Oxidation state of the XRCC1 N-terminal domain regulates DNA polymerase beta binding affinity. Proceedings of the National Academy of Sciences of the United States of America. 2010;107:6805-6810.
Not in our library10.1073/pnas.0914077107
123.
Kelley MR, Georgiadis MM, Fishel ML. APE1/Ref-1 role in redox signaling: translational applications of targeting the redox function of the DNA repair/redox protein APE1/Ref-1. Current molecular pharmacology. 2012;5:36-53.
Not in our library10.2174/1874467211205010036
124.
Luo M, Delaplane S, Jiang A, Reed A, He Y, Fishel M, Nyland RL, Borch RF, Qiao X, Georgiadis MM, Kelley MR. Role of the multifunctional DNA repair and redox signaling protein Ape1/Ref-1 in cancer and endothelial cells: small-molecule inhibition of the redox function of Ape1. Antioxidants & redox signaling. 2008;10:1853-1867.
Not in our library10.1089/ars.2008.2120
125.
Evans AR, Limp-Foster M, Kelley MR. Going APE over ref-1. Mutation research. 2000;461:83-108.
Not in our library10.1016/s0921-8777(00)00046-x
126.
Naidu MD, Mason JM, Pica RV, Fung H, Pena LA. Radiation resistance in glioma cells determined by DNA damage repair activity of Ape1/Ref-1. Journal of radiation research. 2010;51:393-404.
Not in our library10.1269/jrr.09077
127.
Silber JR, Bobola MS, Blank A, Schoeler KD, Haroldson PD, Huynh MB, Kolstoe DD. The apurinic/apyrimidinic endonuclease activity of Ape1/Ref-1 contributes to human glioma cell resistance to alkylating agents and is elevated by oxidative stress. Clinical cancer research. 2002;8:3008-3018.
Not in our library
128.
Bobola MS, Jankowski PP, Gross ME, Schwartz J, Finn LS, Blank A, Ellenbogen RG, Silber JR. Apurinic/apyrimidinic endonuclease is inversely associated with response to radiotherapy in pediatric ependymoma. International journal of cancer. 2011;129:2370-2379.
Not in our library10.1002/ijc.25900
129.
Chen S, Xiong G, Wu S, Mo J. Downregulation of apurinic/apyrimidinic endonuclease 1/redox factor-1 enhances the sensitivity of human pancreatic cancer cells to radiotherapy in vitro. Cancer biotherapy & radiopharmaceuticals. 2013;28:169-176.
Not in our library10.1089/cbr.2012.1266
130.
Ramana CV, Boldogh I, Izumi T, Mitra S. Activation of apurinic/apyrimidinic endonuclease in human cells by reactive oxygen species and its correlation with their adaptive response to genotoxicity of free radicals. Proceedings of the National Academy of Sciences of the United States of America. 1998;95:5061-5066.
Not in our library10.1073/pnas.95.9.5061
131.
Pines A, Perrone L, Bivi N, Romanello M, Damante G, Gulisano M, Kelley MR, Quadrifoglio F, Tell G. Activation of APE1/Ref-1 is dependent on reactive oxygen species generated after purinergic receptor stimulation by ATP. Nucleic acids research. 2005;33:4379-4394.
Not in our library10.1093/nar/gki751
132.
Hsieh MM, Hegde V, Kelley MR, Deutsch WA. Activation of APE/Ref-1 redox activity is mediated by reactive oxygen species and PKC phosphorylation. Nucleic acids research. 2001;29:3116-3122.
Not in our library10.1093/nar/29.14.3116
133.
Bennett SM, Neher TM, Shatilla A, Turchi JJ. Molecular analysis of Ku redox regulation. BMC molecular biology. 2009;10:86.
Not in our library10.1186/1471-2199-10-86
134.
Falck J, Coates J, Jackson SP. Conserved modes of recruitment of ATM, ATR and DNA-PKcs to sites of DNA damage. Nature. 2005;434:605-611.
Not in our library10.1038/nature03442
135.
Andrews BJ, Lehman JA, Turchi JJ. Kinetic analysis of the Ku-DNA binding activity reveals a redox-dependent alteration in protein structure that stimulates dissociation of the Ku-DNA complex. The Journal of biological chemistry. 2006;281:13596-13603.
Not in our library10.1074/jbc.m512787200
136.
Ayene IS, Stamato TD, Mauldin SK, Biaglow JE, Tuttle SW, Jenkins SF, Koch CJ. Mutation in the glucose-6-phosphate dehydrogenase gene leads to inactivation of Ku DNA end binding during oxidative stress. The Journal of biological chemistry. 2002;277:9929-9935.
Not in our library10.1074/jbc.m111366200
137.
Cosentino C, Grieco D, Costanzo V. ATM activates the pentose phosphate pathway promoting anti-oxidant defence and DNA repair. The EMBO journal. 2011;30:546-555.
Not in our library10.1038/emboj.2010.330
138.
Men L, Roginskaya M, Zou Y, Wang Y. Redox-dependent formation of disulfide bonds in human replication protein A. Rapid communications in mass spectrometry: RCM. 2007;21:2743-2749.
Not in our library10.1002/rcm.3144
139.
Penney RB, Roy D. Thioredoxin-mediated redox regulation of resistance to endocrine therapy in breast cancer. Biochimica et biophysica acta. 2013;1836:60-79.
Not in our library10.1016/j.bbcan.2013.02.005
140.
Silber JR, Blank A, Bobola MS, Ghatan S, Kolstoe DD, Berger MS. O6-methylguanine-DNA methyltransferase-deficient phenotype in human gliomas: frequency and time to tumor progression after alkylating agent-based chemotherapy. Clinical cancer research. 1999;5:807-814.
Not in our library
141.
Fu D, Calvo JA, Samson LD. Balancing repair and tolerance of DNA damage caused by alkylating agents. Nature reviews Cancer. 2012;12:104-120.
Not in our library10.1038/nrc3185
142.
Haar CP, Hebbar P, Wallace GCt, Das A, Vandergrift WA, Smith JA, Giglio P, Patel SJ, Ray SK, Banik NL. Drug resistance in glioblastoma: a mini review. Neurochemical research. 2012;37:1192-1200.
Not in our library10.1007/s11064-011-0701-1
143.
Liu L, Gerson SL. Targeted modulation of MGMT: clinical implications. Clinical cancer research. 2006;12:328-331.
Not in our library10.1158/1078-0432.ccr-05-2543
144.
Brown R, Curry E, Magnani L, Wilhelm-Benartzi CS, Borley J. Poised epigenetic states and acquired drug resistance in cancer. Nature reviews Cancer. 2014;14:747-753.
Not in our library10.1038/nrc3819
145.
Ahuja N, Easwaran H, Baylin SB. Harnessing the potential of epigenetic therapy to target solid tumors. The Journal of clinical investigation. 2014;124:56-63.
Not in our library10.1172/jci69736
146.
Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, Kros JM, Hainfellner JA, Mason W, Mariani L, Bromberg JE, Hau P, Mirimanoff RO, Cairncross JG, Janzer RC, Stupp R. MGMT gene silencing and benefit from temozolomide in glioblastoma. The New England journal of medicine. 2005;352:997-1003.
Not in our library10.1056/nejmoa043331
147.
Reliene R, Schiestl RH. Antioxidant N-acetyl cysteine reduces incidence and multiplicity of lymphoma in Atm deficient mice. DNA repair. 2006;5:852-859.
Not in our library10.1016/j.dnarep.2006.05.003
148.
Sablina AA, Budanov AV, Ilyinskaya GV, Agapova LS, Kravchenko JE, Chumakov PM. The antioxidant function of the p53 tumor suppressor. Nature medicine. 2005;11:1306-1313.
Not in our library10.1038/nm1320
149.
Gao P, Zhang H, Dinavahi R, Li F, Xiang Y, Raman V, Bhujwalla ZM, Felsher DW, Cheng L, Pevsner J, Lee LA, Semenza GL, Dang CV. HIF-dependent antitumorigenic effect of antioxidants in vivo. Cancer cell. 2007;12:230-238.
Not in our library10.1016/j.ccr.2007.08.004
150.
Klein EA, Thompson IM, Tangen CM, Crowley JJ, Lucia MS, Goodman PJ, Minasian LM, Ford LG, Parnes HL, Gaziano JM, Karp DD, Lieber MM, Walther PJ, Klotz L, Parsons JK, Chin JL, et al. Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). Jama. 2011;306:1549-1556.
Not in our library10.1001/jama.2011.1437
151.
Omenn GS, Goodman GE, Thornquist MD, Balmes J, Cullen MR, Glass A, Keogh JP, Meyskens FL, Valanis B, Williams JH, Barnhart S, Hammar S. Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease. The New England journal of medicine. 1996;334:1150-1155.
Not in our library10.1056/nejm199605023341802
152.
Piskounova E, Agathocleous M, Murphy MM, Hu Z, Huddlestun SE, Zhao Z, Leitch AM, Johnson TM, DeBerardinis RJ, Morrison SJ. Oxidative stress inhibits distant metastasis by human melanoma cells. Nature. 2015;527:186-191.
Not in our library10.1038/nature15726
153.
Le Gal K, Ibrahim MX, Wiel C, Sayin VI, Akula MK, Karlsson C, Dalin MG, Akyurek LM, Lindahl P, Nilsson J, Bergo MO. Antioxidants can increase melanoma metastasis in mice. Science translational medicine. 2015;7:308re308.
Not in our library10.1126/scitranslmed.aad3740
154.
Lenehan PF, Gutierrez PL, Wagner JL, Milak N, Fisher GR, Ross DD. Resistance to oxidants associated with elevated catalase activity in HL-60 leukemia cells that overexpress multidrug-resistance protein does not contribute to the resistance to daunorubicin manifested by these cells. Cancer chemotherapy and pharmacology. 1995;35:377-386.
Not in our library10.1007/s002800050250
155.
Zhou P, Kalakonda N, Comenzo RL. Changes in gene expression profiles of multiple myeloma cells induced by arsenic trioxide (ATO): possible mechanisms to explain ATO resistance in vivo. British journal of haematology. 2005;128:636-644.
Not in our library10.1111/j.1365-2141.2005.05369.x
156.
Ramanathan B, Jan KY, Chen CH, Hour TC, Yu HJ, Pu YS. Resistance to paclitaxel is proportional to cellular total antioxidant capacity. Cancer research. 2005;65:8455-8460.
Not in our library10.1158/0008-5472.can-05-1162
157.
Hoshida Y, Moriyama M, Otsuka M, Kato N, Taniguchi H, Shiratori Y, Seki N, Omata M. Gene expressions associated with chemosensitivity in human hepatoma cells. Hepato-gastroenterology. 2007;54:489-492.
Not in our library
158.
Zhou Y, Hileman EO, Plunkett W, Keating MJ, Huang P. Free radical stress in chronic lymphocytic leukemia cells and its role in cellular sensitivity to ROS-generating anticancer agents. Blood. 2003;101:4098-4104.
Not in our library10.1182/blood-2002-08-2512
159.
Bahlis NJ, McCafferty-Grad J, Jordan-McMurry I, Neil J, Reis I, Kharfan-Dabaja M, Eckman J, Goodman M, Fernandez HF, Boise LH, Lee KP. Feasibility and correlates of arsenic trioxide combined with ascorbic acid-mediated depletion of intracellular glutathione for the treatment of relapsed/refractory multiple myeloma. Clinical cancer research. 2002;8:3658-3668.
Not in our library
160.
Yoshida T, Goto S, Kawakatsu M, Urata Y, Li TS. Mitochondrial dysfunction, a probable cause of persistent oxidative stress after exposure to ionizing radiation. Free radical research. 2012;46:147-153.
Not in our library10.3109/10715762.2011.645207
161.
Chen P, Wang H, Duan Z, Zou JX, Chen H, He W, Wang J. Estrogen-related receptor alpha confers methotrexate resistance via attenuation of reactive oxygen species production and P53 mediated apoptosis in osteosarcoma cells. BioMed research international. 2014;2014:616025.
Not in our library10.1155/2014/616025
162.
Arnold M, Bissinger R, Lang F. Mitoxantrone-induced suicidal erythrocyte death. Cellular physiology and biochemistry. 2014;34:1756-1767.
Not in our library10.1159/000366376
163.
Lee YH, Kang BS, Bae YS. Premature senescence in human breast cancer and colon cancer cells by tamoxifen-mediated reactive oxygen species generation. Life sciences. 2014;97:116-122.
Not in our library10.1016/j.lfs.2013.12.009
164.
Cisplatin Induces a Mitochondrial-ROS Response That Contributes to Cytotoxicity Depending on Mitochondrial Redox Status and Bioenergetic Functions · 2013
No notice
165.
Liu W, Gu J, Qi J, Zeng XN, Ji J, Chen ZZ, Sun XL. Lentinan exerts synergistic apoptotic effects with paclitaxel in A549 cells via activating ROS-TXNIP-NLRP3 inflammasome. Journal of cellular and molecular medicine. 2015;19:1949-55.
Not in our library10.1111/jcmm.12570
166.
Fan C, Zheng W, Fu X, Li X, Wong YS, Chen T. Strategy to enhance the therapeutic effect of doxorubicin in human hepatocellular carcinoma by selenocystine, a synergistic agent that regulates the ROS-mediated signaling. Oncotarget. 2014;5:2853-2863.
Not in our library10.18632/oncotarget.1854
167.
Tibullo D, Barbagallo I, Giallongo C, La Cava P, Parrinello N, Vanella L, Stagno F, Palumbo GA, Li Volti G, Di Raimondo F. Nuclear translocation of heme oxygenase-1 confers resistance to imatinib in chronic myeloid leukemia cells. Current pharmaceutical design. 2013;19:2765-2770.
Not in our library10.2174/1381612811319150012
168.
Jayasooriya RG, Choi YH, Hyun JW, Kim GY. Camptothecin sensitizes human hepatoma Hep3B cells to TRAIL-mediated apoptosis via ROS-dependent death receptor 5 upregulation with the involvement of MAPKs. Environmental toxicology and pharmacology. 2014;38:959-967.
Not in our library10.1016/j.etap.2014.10.012
169.
Ge Y, Byun JS, De Luca P, Gueron G, Yabe IM, Sadiq-Ali SG, Figg WD, Quintero J, Haggerty CM, Li QQ, De Siervi A, Gardner K. Combinatorial antileukemic disruption of oxidative homeostasis and mitochondrial stability by the redox reactive thalidomide 2-(2,4-difluoro-phenyl)-4,5,6,7-tetrafluoro-1H-isoindole-1,3(2H)-dione (CPS49) and flavopiridol. Molecular pharmacology. 2008;74:872-883.
Not in our library10.1124/mol.107.040808
170.
Gueranger Q, Li F, Peacock M, Larnicol-Fery A, Brem R, Macpherson P, Egly JM, Karran P. Protein oxidation and DNA repair inhibition by 6-thioguanine and UVA radiation. The Journal of investigative dermatology. 2014;134:1408-1417.
Not in our library10.1038/jid.2013.509
171.
Wang J, Yi J. Cancer cell killing via ROS: to increase or decrease, that is the question. Cancer biology & therapy. 2008;7:1875-1884.
Not in our library10.4161/cbt.7.12.7067
172.
Montero AJ, Diaz-Montero CM, Deutsch YE, Hurley J, Koniaris LG, Rumboldt T, Yasir S, Jorda M, Garret-Mayer E, Avisar E, Slingerland J, Silva O, Welsh C, Schuhwerk K, Seo P, Pegram MD, et al. Phase 2 study of neoadjuvant treatment with NOV-002 in combination with doxorubicin and cyclophosphamide followed by docetaxel in patients with HER-2 negative clinical stage II-IIIc breast cancer. Breast cancer research and treatment. 2012;132:215-223.
Not in our library10.1007/s10549-011-1889-0
173.
Lo M, Ling V, Low C, Wang YZ, Gout PW. Potential use of the anti-inflammatory drug, sulfasalazine, for targeted therapy of pancreatic cancer. Current oncology. 2010;17:9-16.
Not in our library10.3747/co.v17i3.485
174.
Guan J, Lo M, Dockery P, Mahon S, Karp CM, Buckley AR, Lam S, Gout PW, Wang YZ. The xc- cystine/glutamate antiporter as a potential therapeutic target for small-cell lung cancer: use of sulfasalazine. Cancer chemotherapy and pharmacology. 2009;64:463-472.
Not in our library10.1007/s00280-008-0894-4
175.
Dufour E, Gay F, Aguera K, Scoazec JY, Horand F, Lorenzi PL, Godfrin Y. Pancreatic tumor sensitivity to plasma L-asparagine starvation. Pancreas. 2012;41:940-948.
Not in our library10.1097/mpa.0b013e318247d903
176.
Pieters R, Hunger SP, Boos J, Rizzari C, Silverman L, Baruchel A, Goekbuget N, Schrappe M, Pui CH. L-asparaginase treatment in acute lymphoblastic leukemia: a focus on Erwinia asparaginase. Cancer. 2011;117:238-249.
Not in our library10.1002/cncr.25489
177.
O'Dwyer PJ, Hamilton TC, LaCreta FP, Gallo JM, Kilpatrick D, Halbherr T, Brennan J, Bookman MA, Hoffman J, Young RC, Comis RL, Ozols RF. Phase I trial of buthionine sulfoximine in combination with melphalan in patients with cancer. Journal of clinical oncology. 1996;14:249-256.
Not in our library10.1200/jco.1996.14.1.249
178.
Lewis-Wambi JS, Kim HR, Wambi C, Patel R, Pyle JR, Klein-Szanto AJ, Jordan VC. Buthionine sulfoximine sensitizes antihormone-resistant human breast cancer cells to estrogen-induced apoptosis. Breast cancer research: BCR. 2008;10:R104.
Not in our library10.1186/bcr2208
179.
Brozovic A, Vukovic L, Polancac DS, Arany I, Koberle B, Fritz G, Fiket Z, Majhen D, Ambriovic-Ristov A, Osmak M. Endoplasmic reticulum stress is involved in the response of human laryngeal carcinoma cells to Carboplatin but is absent in Carboplatin-resistant cells. PloS one. 2013;8:e76397.
Not in our library10.1371/journal.pone.0076397
180.
Yamaguchi H, Hsu JL, Chen CT, Wang YN, Hsu MC, Chang SS, Du Y, Ko HW, Herbst R, Hung MC. Caspase-independent cell death is involved in the negative effect of EGF receptor inhibitors on cisplatin in non-small cell lung cancer cells. Clinical cancer research. 2013;19:845-854.
Not in our library10.1158/1078-0432.ccr-12-2621
181.
Halliwell B. Oxidative stress and cancer: have we moved forward? The Biochemical journal. 2007;401:1-11.
Not in our library10.1042/bj20061131
182.
Takeda S, Nishimura H, Koyachi K, Matsumoto K, Yoshida K, Okamoto Y, Amamoto T, Shindo M, Aramaki H. (−)-Xanthatin induces the prolonged expression of c-Fos through an N-acetyl-L-cysteine (NAC)-sensitive mechanism in human breast cancer MDA-MB-231 cells. The Journal of toxicological sciences. 2013;38:547-557.
Not in our library10.2131/jts.38.547
183.
Zhang Y, Soboloff J, Zhu Z, Berger SA. Inhibition of Ca2+ influx is required for mitochondrial reactive oxygen species-induced endoplasmic reticulum Ca2+ depletion and cell death in leukemia cells. Molecular pharmacology. 2006;70:1424-1434.
Not in our library10.1124/mol.106.024323
184.
Demidem A, Morvan D, Madelmont JC. Bystander effects are induced by CENU treatment and associated with altered protein secretory activity of treated tumor cells: a relay for chemotherapy? International journal of cancer. 2006;119:992-1004.
Not in our library10.1002/ijc.21761
185.
Lin CJ, Lee CC, Shih YL, Lin CH, Wang SH, Chen TH, Shih CM. Inhibition of mitochondria- and endoplasmic reticulum stress-mediated autophagy augments temozolomide-induced apoptosis in glioma cells. PloS one. 2012;7:e38706.
Not in our library10.1371/journal.pone.0038706
186.
Zhu J, Song X, Lin HP, Young DC, Yan S, Marquez VE, Chen CS. Using cyclooxygenase-2 inhibitors as molecular platforms to develop a new class of apoptosis-inducing agents. Journal of the National Cancer Institute. 2002;94:1745-1757.
Not in our library10.1093/jnci/94.23.1745
187.
Gills JJ, Lopiccolo J, Tsurutani J, Shoemaker RH, Best CJ, Abu-Asab MS, Borojerdi J, Warfel NA, Gardner ER, Danish M, Hollander MC, Kawabata S, Tsokos M, Figg WD, Steeg PS, Dennis PA. Nelfinavir, A lead HIV protease inhibitor, is a broad-spectrum, anticancer agent that induces endoplasmic reticulum stress, autophagy, and apoptosis in vitro and in vivo. Clinical cancer research. 2007;13:5183-5194.
Not in our library10.1158/1078-0432.ccr-07-0161
188.
Chen Z, Pittman EF, Romaguera J, Fayad L, Wang M, Neelapu SS, McLaughlin P, Kwak L, McCarty N. Nuclear translocation of B-cell-specific transcription factor, BACH2, modulates ROS mediated cytotoxic responses in mantle cell lymphoma. PloS one. 2013;8:e69126.
Not in our library10.1371/journal.pone.0069126
189.
Kane RC, Dagher R, Farrell A, Ko CW, Sridhara R, Justice R, Pazdur R. Bortezomib for the treatment of mantle cell lymphoma. Clinical cancer research. 2007;13:5291-5294.
Not in our library10.1158/1078-0432.ccr-07-0871
190.
Simunek T, Sterba M, Popelova O, Adamcova M, Hrdina R, Gersl V. Anthracycline-induced cardiotoxicity: overview of studies examining the roles of oxidative stress and free cellular iron. Pharmacological reports: PR. 2009;61:154-171.
Not in our library10.1016/s1734-1140(09)70018-0
191.
Neckers L, Workman P. Hsp90 molecular chaperone inhibitors: are we there yet? Clinical cancer research. 2012;18:64-76.
Not in our library10.1158/1078-0432.ccr-11-1000
192.
Lee RA, Kim HA, Kang BY, Kim KH. Hemoglobin induces colon cancer cell proliferation by release of reactive oxygen species. World journal of gastroenterology. 2006;12:5644-5650.
Not in our library10.3748/wjg.v12.i35.5644
193.
Miller WH, Schipper HM, Lee JS, Singer J, Waxman S. Mechanisms of action of arsenic trioxide. Cancer research. 2002;62:3893-3903.
Not in our library
194.
Zhang Q, Ma Y, Cheng YF, Li WJ, Zhang Z, Chen SY. Involvement of reactive oxygen species in 2-methoxyestradiol-induced apoptosis in human neuroblastoma cells. Cancer letters. 2011;313:201-210.
Not in our library10.1016/j.canlet.2011.09.005
195.
Lai WL, Wong NS. ROS mediates 4HPR-induced posttranscriptional expression of the Gadd153 gene. Free radical biology & medicine. 2005;38:1585-1593.
Not in our library10.1016/j.freeradbiomed.2005.02.024
196.
Luo X, Kraus WL. On PAR with PARP: cellular stress signaling through poly(ADP-ribose) and PARP-1. Genes & development. 2012;26:417-432.
Not in our library10.1101/gad.183509.111
197.
Dixon SJ, Lemberg KM, Lamprecht MR, Skouta R, Zaitsev EM, Gleason CE, Patel DN, Bauer AJ, Cantley AM, Yang WS, Morrison B, Stockwell BR. Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell. 2012;149:1060-1072.
Not in our library10.1016/j.cell.2012.03.042
198.
Yagoda N, von Rechenberg M, Zaganjor E, Bauer AJ, Yang WS, Fridman DJ, Wolpaw AJ, Smukste I, Peltier JM, Boniface JJ, Smith R, Lessnick SL, Sahasrabudhe S, Stockwell BR. RAS-RAF-MEK-dependent oxidative cell death involving voltage-dependent anion channels. Nature. 2007;447:864-868.
Not in our library10.1038/nature05859

Cited by papers we hold 3

Drug Resistance in Glioblastoma: The Two Faces of Oxidative Stress · 2021
No notice
Understanding of ROS-Inducing Strategy in Anticancer Therapy · 2019
No notice
Redox regulation in tumor cell epithelial–mesenchymal transition: molecular basis and therapeutic strategy · 2017
No notice

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.